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The MBD4 gene encodes a thymine glycosylase that binds to DNA
at methyl-CpG dinucleotide sites and can excise the thymine
base at a T.G mismatched basepair resulting from deamination of 
the methyl-C (Hendrich and Bird, 1998; Bellacosa et al, 1999;
Hendrich et al, 1999). The gene is therefore thought to be an
important component of the system that maintains the integrity of
methylation patterns throughout the genome, and so silencing of
gene transcription. MBD4 contains a polynucleotide stretch of 10
adenines (A10) within one translated exon that we and others have
found to be mutated in at least 25% of mismatch repair defective
(RER+) colorectal tumours (Bader et al, 1999; Riccio et al, 1999).
The mutation involves either gain or loss of one base and in either
case is predicted to cause a premature cessation of translation and
production of non-functional protein. It has been suggested from
in vitro studies (Bellacosa et al, 1999) that MBD4 may play a role
in the cause of microsatellite instability but this would not be
borne out by our observations of mutations seen in vivo for several
reasons. Firstly, mutations within the A10 tract would generate a
truncated protein that has lost domains including that shown to
interact with MLH1. Secondly, the apparently relatively low
frequency of mutation and the strict association of mutation with
the RER+ phenotype strongly suggests that MBD4 abnormalities
are actually downstream from mismatch repair (MMR) gene
defects. Here we report more accurately the frequency and timing
of MBD4 mutation in established RER+ sporadic colorectal carcin-
omas by microdissecting multiple and independent formalin-fixed,
paraffin-embedded tumour sections to ensure less than 5% stromal
contamination. 
MATERIALS AND METHODS 
Patients studied were all of those used before in Bader et al (1999)
which were microsatellite unstable. 10 µ m sections were cut
from 10% formalin-fixed paraffin-embedded tissues, dewaxed and
stained with eosin. These were aligned with haematoxylin & eosin
stained contiguous sections previously scrutinized and marked to
identify tumour-rich areas. Selected areas were covered with 10 µ l
deionized water, scraped with a fresh scalpel blade and transferred
into a sterile microfuge tube. The tissue suspension was digested
with proteinase K overnight at 42˚C, then extracted once with
phenol and chloroform, ethanol precipitated and resuspended in
deionized water. Each microdissected site was derived from a
section made from an independent paraffin-embedded tumour
block, and so represented a region from the same tumour but phys-
ically separated from other microdissected sites. PCR amplifica-
tion and SSCP analyses were done as described in Bader et al
(1999). 
RESULTS 
Mutations were identified in many of the microdissected sites
taken from the same patients as originally assayed from frozen
tumour samples. We detected mutations in at least one site in 17
of 19 (89%) primary tumours (see Table 1). Some of these, for
example case 7 sites b and c, show reduction to homozygosity.
In three cases (8, 9 and 15) we found no mutations in micro-
dissected sites despite a mutation in the frozen sample. This was
probably a chance occurrence due to different sites of sampling
picking up the heterogeneity present in the tumour of these
patients. This is easily true for cases 9 and 15 where only three
sites were assayed. Figure 1 shows the results for three example
cases where whole tissue tumour sample originally gave a nega-
tive (apparent lack of mutation) result. Within each tumour there
was considerable heterogeneity, implying that the point during
clonal development of each tumour when the MBD4 gene
sustains mutation may occur late after tumorigenesis has
occurred. Theoretically it is possible that a loss or gain of a base
could be reverted due to the continuing microsatellite unstable
environment, but this is unlikely. Clearly, MBD4 is not mutated
in the founder clone of any tumour, nor is it mutated at as early a
stage as reported for transforming growth factor β type II
receptor (TGFβ RII). However 11 of the 17 (65%) cases positive
for  MBD4 mutation had abnormalities in a majority of sites
(more than 50% of all sites tested), suggesting that mutation can
be relatively early. 
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Table 1 MBD4 mutations of RER+ sporadic colorectal cancers.
Case Microdissected site  Frozen  Microdissected  Dukes  
in primary tumour tissue data* data‡ stage
c1 wt B 
aw t
b wt 
c wt 
c2 wt B 
a wt/–1 
b –1 
c wt 
c3 wt B 
a wt/–1 
b wt/–1 
c wt/–1 
c4 wt B 
a wt 
b wt 
c wt 
d wt/–1 
c5 wt A 
a wt 
b wt 
c wt/–1 
c7 wt B 
a wt 
b –1 
c –1 
d wt 
e wt/–1 
c8 wt/–1 B 
a wt 
b wt 
c wt 
d wt 
e wt 
c9 wt/–1 B 
a wt 
b wt 
c10 wt/–1 B 
a wt 
b wt/–1 
c11 wt/–1 C 
a wt 
b wt 
c wt/–1 
c13 wt B 
a wt 
b wt 
c wt 
d wt 
e wt 
f wt/–1 
g wt 
h wt 
c14 wt A 
a wt/–1 
b wt/–1 
c15 wt/–1 A 
a wt 
b wt 
c16 wt/–1 A 
a wt/–1 
b wt 
c17 wt C
a wt/+1 
b –1 
c wt/+1 
d wt/–1/+1 1648 S Bader et al
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DISCUSSION 
We have found, upon analysis of microdissected sites rather than
total tumour tissue, that MBD4 mutations occur in 89% of
colorectal cancers. This is significantly more frequent than in
previous reports (43% in Bader et al (1999), 25% in Riccio et al
(1999)). There is, however, a wide range in proportion of mutation
positive tumour areas within any one case. Such intratumoral
heterogeneity of exonic polynucleotide tracts within sporadic
colorectal and other cancers has been documented recently
(Abdel-Rahman et al, 1999; Chung et al, 1999; Samowitz and
Slattery, 1999), and implies a late occurrence of mutations in a
gene during the progression of the tumour. Thus, MBD4 is not
mutated as frequently or as early in tumorigenesis as is the
TGFβ RII gene (Markowitz et al, 1995), but mutation is not as rare
as for IGFIIR gene (Souza et al, 1996). 
It is possible that the observed pattern of MBD4 mutation merely
reflects a non-functional consequence of microsatellite instability at
this locus. However, mutations in MBD4 downstream of MMR
gene defects could still be important such that MBD4 lack of repair
of T.G mismatches compounds the MMR defects. The additional
mutation load could either promote progression along the tumori-
genic pathway, or may help to explain why many RER+ tumours
have a better stage-specific prognosis (Bubb et al, 1996; Sankila et
al, 1996). The suggestion that MBD4 could be a tumour suppressor
gene remains valid regarding biallelic inactivation. We found in this
study frequent reduction to homozygosity, or the presence of +1
and –1 adenine biallelic mutation (for example Figure 1, case 17),
and loss of heterozygosity of neighbouring polymorphic markers
has also been reported (Riccio et al, 1999). The question thus
remains, regarding the nature of the proposed biological signifi-
cance of truncated forms of MBD4 protein at late stages of tumour
development. We have hypothesized a dominant negative or gain of
function phenotype in cells that are even only heterozygous for the
frameshift mutations (Bader et al, 1999) and experiments to test this
hypothesis are in progress. Hendrich and Bird (1998) have already
shown in vitro that C-terminal deleted forms of MBD4 can still
efficiently bind to methyl-CpG. 
In summary, mutations occur in MBD4 at higher frequencies
than originally observed and to a significant degree as biallelic
inactivation. It has been previously concluded that MBD4 alter-
ations occur as a downstream event from MMR gene mutation but
the results presented here suggest that clonal mutations of MBD4
may nevertheless play a significant role in disease evolution.
These observations, together with the proposed function of the
protein, suggest intriguingly that MBD4 is important in deter-
mining the phenotype of RER+ sporadic colorectal tumours,
particularly the later phases of malignancy. 
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Figure 1 Mutation of MBD4 in microdissected sites of three example cases.
‘N’ indicates a sample of frozen whole normal colon mucosa; ‘T’ indicates a
sample of frozen whole colorectal tumour; ‘a–e’ represent independent sites
microdissected from paraffin sections.
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